Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
With the previous incumbent withdrawn from the market Ascendis hails a new hormone replacement for hypoparathyroidism.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Several key data readouts slated for the first quarter remain unannounced, from Roche, Lilly, Axsome and others, but the Covid-19 pandemic puts many at risk of delay.
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.